홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Oxazolidin

HCID 4641
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
129-20-4
표준 SMILES
CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O
InChIKey
HFHZKZSRXITVMK-UHFFFAOYSA-N
분자식
C19H20N2O3
평균 분자량
324.4 g/mol
단동위원소 질량
324.1473925

개요

Oxyphenbutazone is a metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. It has a role as an antimicrobial agent, a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic, an antineoplastic agent, a gout suppressant, a drug metabolite and a xenobiotic metabolite. It is a member of phenols and a member of pyrazolidines. It is functionally related to a phenylbutazone.

이름 및 식별자

우선 이름
Oxazolidin
IUPAC
4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
영어명
Oxyphenyl butazone
분자식
C19H20N2O3
분자량
324.37

이름 및 동의어

oxyphenbutazone129-20-4OxyphenylbutazoneTandearilFlogitoloFlogorilFrabelOxalidNeo-FarmadolCrovarilOxazolidinVisubutina
이름 더 보기
bm1BM 1Flogalg27202IridilMysiteNeofen
OxifenylbutazonOxiphenbutazoneButapironeCalifornitTandacoteFlamarilOxyphenobutazonep-Oxyphenylbutazone

데이터베이스 식별자

CAS
129-20-4、7081-38-1
PubChem CID
4641
DTXSID
DTXSID1045291
ChEMBL
CHEMBL1228、CHEMBL3989676
ChEBI
CHEBI:76258
UNII
A7D84513GV
EC Number
204-936-2
Nikkaji
J10.648H

물성

구조 계산 물성

XLogP
2.7
극성 표면적
60.9 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
3
회전 가능 결합 수
5
무거운 원자 수
24
형식 전하
0
복잡도
454

실험 및 물리화학적 성질

LogP3.04
OdorODORLESS
Color/FormWHITE TO YELLOWISH WHITE, CRYSTALLINE POWDER
Solubility · 2건

ANHYDROUS CRYSTALS FROM ETHER & PETROLEUM ETHER WITH MP 124-125 °C; ACIDIC REACTION; MP 96 °C; FORMS WATER-SOL SODIUM SALT; SOL IN ETHANOL, METHANOL, CHLOROFORM, BENZENE, ETHER /MONOHYDRATE/

VERY SLIGHTLY SOL IN WATER; FREELY SOL IN ACETONE

Human Drugs · 3건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Collision Cross Section · 3건

163.33 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

177.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

184.74 Ų [M-H]-

물리화학적 성질

녹는점
109 · 109-111°C
끓는 점
462.71 °C · 462.71°C (rough estimate)
밀도
1.2118 · 1.2118 (rough estimate)
굴절률

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Other Safety InformationIMAP assessments - 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

독성 정보

Interactions · 5건

SOME TRICYCLIC COMPD HAVE BEEN SHOWN TO DELAY OXYPHENYLBUTAZONE ABSORPTION IN RAT BY INCR GASTRIC EMPTYING TIME.

...OXYPHENBUTAZONE MAY PROLONG PROTHROMBIN TIME IN PT RECEIVING COUMARIN ANTICOAGULANTS CONCOMITANTLY & MAY INCR HYPOGLYCEMIC EFFECT OF INSULIN & ORAL HYPOGLYCEMIC AGENTS.

WHEN OXYPHENBUTAZONE & METHANDROSTENOLONE ARE ADMIN CONCURRENTLY IN HUMANS, SERUM OXYPHENBUTAZONE LEVELS MAY BE ELEVATED. PT TREATED WITH THESE CONCURRENTLY SHOULD BE MONITORED FOR SIGNS OF OXYPHENBUTAZONE-INDUCED ADVERSE EFFECTS.

OXYPHENBUTAZONE ABSORPTION...IS DECR BY DESIPRAMINE.

For more Interactions (Complete) data for OXYPHENBUTAZONE (6 total), please visit the HSDB record page.

Human Toxicity Excerpts · 5건

NAUSEA, VOMITING, EPIGASTRIC DISCOMFORT, & SKIN RASHES ARE MOST FREQUENTLY REPORTED UNTOWARD EFFECTS. DIARRHEA, VERTIGO, INSOMNIA, EUPHORIA, NERVOUSNESS, HEMATURIA...& BLURRED VISION HAVE ALSO BEEN OBSERVED. ...WATER & ELECTROLYTE RETENTION & EDEMA FORMATION OCCUR. /PHENYLBUTAZONE/

화학 및 산업

약리 정보

ATC Code · 6건

S - Sensory organs

M - Musculo-skeletal system

M - Musculo-skeletal system

QM - Musculo-skeletal system

QS - Sensory organs

QM - Musculo-skeletal system

Mechanism of Action · 1건

...HAS PROMINENT ANTI-INFLAMMATORY EFFECTS IN ANIMALS, & COMPARABLE EFFECTS... IN PT WITH RHEUMATOID ARTHRITIS & RELATED DISORDERS. ...INHIBITS BIOSYNTHESIS OF PROSTAGLANDINS, UNCOUPLES OXIDATIVE PHOSPHORYLATION, & INHIBITS ATP-DEPENDENT BIOSYNTHESIS OF MUCOPOLYSACCHARIDE SULFATES IN CARTILAGE. /PHENYLBUTAZONE/

Biological Half-LifeIN MAN, OXYPHENBUTAZONE HAS BIOLOGICAL HALF-LIFE OF ABOUT 2 DAYS.
Metabolism/MetabolitesOXIDN OF PHENYLBUTAZONE DURING CHRONIC DOSING BY MEASURING URINARY EXCRETION OF 3 METABOLITES, OXYPHENBUTAZONE GAMMA-HYDROXYPHENBUTAZONE & P,GAMMA-HYDROXYPHENBUTAZONE DURING INFUSION OF HYDROCORTISONE SODIUM SUCCINATE IS REPORTED.
MeSH Pharmacological Classification · 1건

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Absorption, Distribution and Excretion · 1건

...OXYPHENBUTAZONE IS EXTENSIVELY BOUND TO PLASMA PROTEINS & HAS PLASMA HALF-TIME OF SEVERAL DAYS. ...ONLY SLOWLY EXCRETED IN URINE, SINCE BINDING TO PLASMA PROTEIN LIMITS...GLOMERULAR FILTRATION, &...RELATIVELY HIGH PKA, WHICH FAVORS PASSIVE REABSORPTION IN DISTAL TUBULE.

용도 및 제조

관련 반응

5건
반응 기록 만들기
HRID 259177 반응식
HRID 259177반응물로
HRID 1076799 반응식
HRID 1076799반응물로
HRID 1390723 반응식
HRID 1390723반응물로
HRID 1764768 반응식
HRID 1764768반응물로
HRID 1863518 반응식
HRID 1863518반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
1.614 · 1.6140 (estimate)
저장 조건
-20 °C · -20°C
용해도
10 mg/mL, · DMSO: 용해성10mg/mL, 투명
산도 계수 (pKa)
4.7 · pKa 4.7/10.0±0.2(H2O,t =25,Iundefined) (Uncertain)
물리적 상태
가루
색상
흰색에서 갈색으로
수용성
20 mg/L · 20mg/L(상온)
안정성
흡습성
InChI
1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
InChIKey
HFHZKZSRXITVMK-UHFFFAOYSA-N
SMILES
N2(N(C(=O)C(C2=O)CCCC)c3ccccc3)c1ccc(cc1)O
EPA
3 · 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl- (129-20-4)

화학적 성질

Light Beige Solid

MORE SERIOUS FORMS OF ADVERSE EFFECTS INCL PEPTIC ULCER...WITH HEMORRHAGE OR PERFORATION, HYPERSENSITIVITY REACTIONS OF SERUM-SICKNESS TYPE, ULCERATIVE STOMATITIS, HEPATITIS, NEPHRITIS, APLASTIC ANEMIA, LEUKOPENIA, AGRANULOCYTOSIS, & THROMBOCYTOPENIA. NUMBER OF DEATHS HAVE OCCURRED... /PHENYLBUTAZONE/

...32-YR OLD WOMAN WHO WAS TREATED WITH 2.5 G OXYPHENBUTAZONE OVER 7 DAYS; SHE...DEVELOPED SEVERE LEUCOCYTOSIS FOLLOWED BY LEUCOPENIA & ANEMIA...SUBSEQUENT RECOVERY.

ADMIN OF PHENYLBUTAZONE...IS ASSOC WITH...BONE MARROW SUPPRESSION. TOXICITY OF OXYPHENBUTAZONE IS SIMILAR TO THAT OF PARENT COMPD... /PHENYLBUTAZONE/

NUMBER OF CASES OF LEUKEMIA WERE REPORTED BETWEEN 1960 & 1966 IN SUBJECTS TREATED WITH PHENYLBUTAZONE OR OXYPHENBUTAZONE. AVAIL EVIDENCE IS, HOWEVER, INSUFFICIENT TO SUBSTANTIATE SUGGESTION THAT USE...IS RELATED TO SUBSEQUENT DEVELOPMENT OF LEUKEMIA.

Carcinogen Classification · 5건

Oxyphenbutazone

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 13: (1977) Some Miscellaneous Pharmaceutical Substances

1987

1987

Drug Induced Liver Injury · 4건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Oxyphenbutazone

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 2건

.../PHENYLBUTAZONE/ DID NOT INDUCE NON-DISJUNCTION OR CROSSING-OVER IN ASPERGILLUS NIDULANS IN ABSENCE OF METABOLIC ACTIVATION, WHEREAS ITS METABOLITE, OXYPHENBUTAZONE, HAD WEAK BUT SIGNIFICANT ACTIVITY.

GASTRIC ULCERATIONS WERE PRODUCED IN DOGS AFTER PROLONGED IM ADMIN OF DOSES OF 3.6-35.2 G PHENYLBUTAZONE OVER 10-103 DAYS. /PHENYLBUTAZONE/

Evidence for CarcinogenicityNo data are available in humans. No data are available in animals. OVERALL EVALUATION: Group 3: The agent is not classifiable as to its carcinogenicity to humans.

안전 데이터

wgk
3
ridadr
UN 3077 9 / PGIII
HS 번호
2933990099
risk_code
22-50
hazard_code
Xn,N
safety_code
61
Hazard Classifications
Acute Tox. 4 OralAquatic Acute 1
스토리지 클래스
11 - Combustible Solids
유해 물질 데이터
129-20-4(Hazardous Substances Data)
Uses · 2건

MEDICATION

MEDICATION (VET)

Methods of ManufacturingHAFLIGER, US PATENT 2,745,783 (1956 TO GEIGY): PFISTER, HAFLIGER, HELV CHIM ACTA 40, 395 (1957).
Formulations/PreparationsOXYPHENBUTAZONE, NF (TANDEARIL), IS MARKETED IN 100-MG TABLETS.
Use ClassificationPharmaceuticals
General Manufacturing Information · 1건

OXYPHENBUTAZONE IS HYDROXY ANALOG OF PHENYLBUTAZONE & ONE OF MAJOR ACTIVE METABOLITES OF PARENT DRUG. ... OXYPHENBUTAZONE HAS SAME SPECTRUM OF ACTIVITY, THERAPEUTIC USES, INTERACTIONS, & TOXICITY AS PARENT COMPD, & IT SHARES SAME INDICATIONS, DANGERS, & CONTRAINDICATIONS FOR CLINICAL USE.

응용 분야 · 2건

용도Anti-inflammatory;Cyclooxygenase inhibito

일반 설명Oxyphenbutazone is a derivative compound of phenylbutazone. Oxyphenbutazone is one of the metabolites formed in the liver following administration of phenylbutazone. Given orally it causes fewer gastrointestinal adverse effects than phenylbutazone and is used at 300 – 400 mg/d for the same indications as the parent drug.

상·하류 제품 정보

상류 원료

1-페닐-2-[4-(페닐메톡시)페닐]하이드라진수소나트륨
추가 설명 · 1건

정의ChEBI: A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following asso iation with blood dyscrasis and Stevens-Johnson syndrome.